Patients with psoriatic arthritis (PsA) have a higher prevalence of diabetes mellitus (DM) compared to the general population ...

Objective Rheumatoid arthritis (RA) and Sjögren’s disease (SjD) are two rheumatic autoimmune diseases that commonly co-occur. Besides some overlap in clinical presentation, the two diseases share the ...

The cellular composition and underlying spatiotemporal transformation processes of subchondral bone in osteoarthritis (OA) remain unknown. Herein, various cell subsets from tibial plateau of patients ...

Systemic lupus erythematosus (SLE) is a heterogenic connective tissue disease with a broad spectrum of clinical and laboratory manifestations. Due to this heterogeneity, SLE remains challenging to ...

Objective To determine the contribution of clinical and biochemical inflammation to structural progression of patients with psoriatic arthritis (PsA).Methods We analysed patients from the Infliximab ...

Objective This study assessed the early effects of ozoralizumab (OZR) 30 mg in patients with rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX-IR), drawing on OHZORA trial data ...

There is a growing interest in patient-reported outcomes (PROs) in rheumatology, which goes with a global trend for more ‘patient-centred care’. This review considers the use of PROs in trials, ...

The objective of this paper is to describe the phenotype compound heterozygote for mutations in CECR1 in two children. We describe the clinical and immunological phenotype, including the assessment of ...

Objective To compare the real-word effectiveness of subcutaneous tocilizumab (TCZ-SC) and intravenous tocilizumab (TCZ-IV) in rheumatoid arthritis (RA).Methods Patients with RA with TCZ from eight ...

Background Sex differences in phenotype presentation, disease trajectory and treatment response in psoriatic arthritis (PsA) have been reported. Nevertheless, whether classes of targeted therapies ...

Background The potential benefit of methotrexate (MTX) in combination with biologic (b) and targeted synthetic (ts) disease modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA) is ...